nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors
|
Schirosi, L. |
|
|
23 |
9 |
p. 2409-2414 |
artikel |
2 |
Addition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer
|
Bian, S.X. |
|
|
23 |
9 |
p. 2346-2352 |
artikel |
3 |
Alcohol drinking and risk of renal cell carcinoma: results of a meta-analysis
|
Bellocco, R. |
|
|
23 |
9 |
p. 2235-2244 |
artikel |
4 |
A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors
|
Strosberg, J.R. |
|
|
23 |
9 |
p. 2335-2341 |
artikel |
5 |
A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy
|
Baumann, K.H. |
|
|
23 |
9 |
p. 2265-2271 |
artikel |
6 |
A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up
|
Johnston, S.J. |
|
|
23 |
9 |
p. 2296-2300 |
artikel |
7 |
A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study
|
Sehouli, J. |
|
|
23 |
9 |
p. 2259-2264 |
artikel |
8 |
Bone matters in lung cancer
|
Brodowicz, T. |
|
|
23 |
9 |
p. 2215-2222 |
artikel |
9 |
Calpain system protein expression in basal-like and triple-negative invasive breast cancer
|
Storr, S.J. |
|
|
23 |
9 |
p. 2289-2296 |
artikel |
10 |
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
|
Santini, D. |
|
|
23 |
9 |
p. 2313-2318 |
artikel |
11 |
Changes in survival by ethnicity of patients with cancer between 1992–1996 and 2002–2006: is the discrepancy decreasing?
|
Pulte, D. |
|
|
23 |
9 |
p. 2428-2434 |
artikel |
12 |
Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses
|
Pierceall, W.E. |
|
|
23 |
9 |
p. 2245-2252 |
artikel |
13 |
Clinical correlates of ‘BRCAness’ in triple-negative breast cancer of patients receiving adjuvant chemotherapy
|
Oonk, A.M.M. |
|
|
23 |
9 |
p. 2301-2305 |
artikel |
14 |
Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer†
|
Xu, C.F. |
|
|
23 |
9 |
p. 2470-2471 |
artikel |
15 |
Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma
|
Bachet, J.B. |
|
|
23 |
9 |
p. 2327-2335 |
artikel |
16 |
DNA repair protein expression in resected NSCLC: a different predictive value for platinum benefit in adenocarcinoma versus squamous-cell carcinoma?
|
Felip, E. |
|
|
23 |
9 |
p. 2211-2214 |
artikel |
17 |
Editorial Board
|
|
|
|
23 |
9 |
p. ii-iii |
artikel |
18 |
Effect of radiation therapy on survival in surgically resected retroperitoneal sarcoma: a propensity score-adjusted SEER analysis
|
Choi, A.H. |
|
|
23 |
9 |
p. 2449-2457 |
artikel |
19 |
Elevated serum antibodies against insulin-like growth factor-binding protein-2 allow detecting early-stage cancers: evidences from glioma and colorectal carcinoma studies
|
Li, Y. |
|
|
23 |
9 |
p. 2415-2422 |
artikel |
20 |
Extracorporeal photopheresis as a curative treatment strategy in non epidermotropic T-cell lymphoma and large granular lymphocyte leukemia
|
Garban, F. |
|
|
23 |
9 |
p. 2386-2390 |
artikel |
21 |
Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402)
|
Niho, S. |
|
|
23 |
9 |
p. 2253-2258 |
artikel |
22 |
Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients
|
Solomayer, E.-F. |
|
|
23 |
9 |
p. 2271-2277 |
artikel |
23 |
Menstrual and reproductive factors, and hormonal contraception use: associations with non-Hodgkin lymphoma in a pooled analysis of InterLymph case–control studies
|
Kane, E.V. |
|
|
23 |
9 |
p. 2362-2374 |
artikel |
24 |
Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer
|
Schmidt, M. |
|
|
23 |
9 |
p. 2306-2313 |
artikel |
25 |
Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer
|
Jensen, L.H. |
|
|
23 |
9 |
p. 2341-2346 |
artikel |
26 |
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness
|
Czuczman, M.S. |
|
|
23 |
9 |
p. 2356-2362 |
artikel |
27 |
Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors
|
Markman, B. |
|
|
23 |
9 |
p. 2399-2408 |
artikel |
28 |
Population survival from childhood cancer in Britain during 1978–2005 by eras of entry to clinical trials
|
Stiller, C.A. |
|
|
23 |
9 |
p. 2464-2469 |
artikel |
29 |
Preoperative PET/CT in early-stage breast cancer
|
Bernsdorf, M. |
|
|
23 |
9 |
p. 2277-2282 |
artikel |
30 |
Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL): experience from the G-PCNSL-SG1 trial
|
Korfel, A. |
|
|
23 |
9 |
p. 2374-2380 |
artikel |
31 |
Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a CellSearch analysis
|
Gazzaniga, P. |
|
|
23 |
9 |
p. 2352-2356 |
artikel |
32 |
Red and processed meat consumption and the risk of esophageal and gastric cancer subtypes in The Netherlands Cohort Study
|
Keszei, A.P. |
|
|
23 |
9 |
p. 2319-2326 |
artikel |
33 |
Reproductive and hormonal risk factors for luminal, HER2-overexpressing, and triple-negative breast cancer in Japanese women
|
Islam, T. |
|
|
23 |
9 |
p. 2435-2441 |
artikel |
34 |
Resumption or persistence of menstruation after cytotoxic chemotherapy is a prognostic factor for poor disease-free survival in premenopausal patients with early breast cancer
|
Park, I.H. |
|
|
23 |
9 |
p. 2283-2289 |
artikel |
35 |
Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up
|
Colombat, P. |
|
|
23 |
9 |
p. 2380-2385 |
artikel |
36 |
Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions
|
Ray-Coquard, I. |
|
|
23 |
9 |
p. 2442-2449 |
artikel |
37 |
Table of Contents
|
|
|
|
23 |
9 |
p. iv-vi |
artikel |
38 |
Targeting triple-negative breast cancer: optimising therapeutic outcomes
|
Gelmon, K. |
|
|
23 |
9 |
p. 2223-2234 |
artikel |
39 |
The role of comorbidities on the uptake of systemic treatment and 3-year survival in older cancer patients
|
Stavrou, E.P. |
|
|
23 |
9 |
p. 2422-2428 |
artikel |
40 |
Treatment and outcome of Wilms' tumour patients: an analysis of all cases registered in the UKW3 trial
|
Pritchard-Jones, K. |
|
|
23 |
9 |
p. 2457-2463 |
artikel |
41 |
Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy
|
Sher, D.J. |
|
|
23 |
9 |
p. 2391-2398 |
artikel |